Cohort 2 was used for the comparison of the two protocols and consisted of eight adolescents who participated in a phase IV Booster trial conducted at the Swedish Institute for Communicable Disease Control (EUDRACT no 2008-008195-13). Four of the subjects were given the same booster dose as cohort 1 and four subjects were given one dose of vaccine containing ≥ 20 IU TTd, ≥ 2 IU DT and 20 μg PT, (diTekiBooster DTPa1, Statens Serum Institut, Copenhagen, Denmark).

Blood was drawn at day 0 (pre-vaccination sample) and between days 28–42 (post-vaccination sample). PT (lot 042) and FHA (lot 039) were obtained from Kaketsuken Selleckchem GSK126 (Kumamoto, Japan). PRN (lot 180805 RS) was kindly provided by A.M. Buisman from RIVM (Bilthoven, the Netherlands). TTd was obtained from Statens Serum Institut (SSI) (Copenhagen, Denmark) and DT was from Statens Bakteriologiska Laboratorium (SBL) (Solna, Sweden). For the initial protocol optimization studies, PBMC were Ficoll-isolated from buffy coats and cryopreserved as previously described (Minang Ceritinib concentration et al., 2006). For the assessment of vaccine-induced responses, whole blood was collected in BD Vacutainer® CPT tubes with sodium

heparin (Becton Dickinson, Franklin Lakes, NJ, USA) and separated according to the manufacturer’s instruction. Cryopreservation and thawing were performed as previously described (Nilsson et al., 2008) using a freezing medium Endonuclease with 90% Fetal Calf Serum (FCS) (Gibco Invitrogen, Paisley, UK) and 10% Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA). Mouse hybridomas were generated against a mix of human IgG1-4 subclasses (Sigma-Aldrich) and monoclonal antibodies (mAbs) were identified by ELISA screening for reactivity with IgG1-4 separately, as well as serum-derived IgG; the lack of mAb reactivity with human IgA, IgM (Jackson ImmunoResearch Laboratories Inc., Baltimore, PA, USA) and IgE (Mabtech, Nacka Strand, Sweden) was also confirmed. MAbs displaying comparable reactivity with all subclasses and total IgG were evaluated as capture and biotinylated

detection reagents in ELISA using methods as described in Zuber et al. (2005). The combination of two capture mAbs (MT91/145) and two biotinylated detection mAbs (MT78/145) was defined by ELISA as the optimal capture assay displaying equal reactivity with all human IgG subclasses. The functionality of the mAb reagents in B-cell ELISpot was confirmed as described below. After thawing, PBMC were rested for 1 h in humidity at 37 °C, 5% CO2 and divided into stimulated or unstimulated cells. To the stimulated cells, 1 μg/ml R848 (Mabtech) and 10 ng/ml recombinant human (rh)IL-2 (Mabtech) were added. Cells were subsequently incubated in culture flasks for three days at 37 °C, 5% CO2. During the optimization evaluation, other incubation times and activators were used as indicated elsewhere.